ArticleQuantitative imaging in medicine and surgery2025
The capacity of subtraction CT iodine maps to improve the differentiation of solitary pulmonary nodules.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of benign and malignant pulmonary nodules based on clinical and contrast-enhanced computed tomography data: a multicenter study.Quantitative imaging in medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Solitary pulmonary nodules (SPNs) are common incidental findings for which accurate characterization remains challenging on conventional computed tomography (CT), where phase-to-phase attenuation differences can yield equivocal results. Subtraction CT (SCT) generates motion-compensated iodine maps that quantify enhancement more robustly and can offer higher contrast-to-noise ratio (CNR) and lower dose than dual-energy CT (DECT). However, its value for differentiating SPNs has not been established. The aim of this study was to evaluate the diagnostic performance of iodine map metrics derived from SCT for differentiating SPNs and to assess their incremental value over that of conventional morphological features. Methods: A total of 91 patients with pathologically confirmed SPNs (44 malignant, 25 benign, 22 inflammatory) were retrospectively analyzed. All underwent triple-phase SCT [non-contrast-enhanced phase (NC), arterial enhanced phase (AP), and venous enhanced phase (VP)] to generate subtraction iodine map of AP (SubA) and subtraction iodine map of VP (SubV) iodine maps. Nine CT value metrics were assessed. Interobserver agreement was evaluated using intraclass correlation coefficients (ICC). Diagnostic performance was analyzed using receiver operating characteristic (ROC) curves and DeLong tests. Results: Five core metrics (NC, AP, VP, SubA, SubV) demonstrated excellent interobserver agreement (ICC >0.89). Hounsfield units (HU) of SubA showed the highest stability and significant differences across all three groups (benign: 21.2±11.1 HU, malignant: 34.5±16.6 HU, inflammatory: 43.9±10.7 HU, all P<0.05). SubA achieved the highest area under the curve (AUC) in distinguishing benign from inflammatory nodules (AUC =0.95, sensitivity =88%, specificity =95%). Combined models incorporating both SubA and morphological features improved diagnostic accuracy for all comparisons, significantly increasing AUCs for benign Conclusions: Quantitative iodine values from SCT, particularly SubA, enhance the differentiation of SPNs with higher stability and diagnostic performance than conventional methods. The integration of SCT iodine maps with morphological assessment significantly improves diagnostic accuracy and supports clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.